Best Peptides for Fat Loss

Educational content only. Not medical advice. Weight management decisions involve significant medical considerations; consult a licensed healthcare provider.

Overview

Fat loss peptides are short chains of amino acids that influence the metabolic pathways governing appetite, energy expenditure, lipolysis, and glucose handling. Two of them — semaglutide and tirzepatide — have changed obesity medicine, and the trial data behind them is unusually strong. The rest of this category is much weaker than the marketing suggests, and this hub tries to keep the two apart.

There are two principal mechanism families to understand:

1. GLP-1 / incretin receptor agonists — peptides that act at gut-hormone receptors to reduce appetite, slow gastric emptying, and improve insulin signaling. This family includes the compounds most people mean by best peptides for fat loss: semaglutide, tirzepatide, retatrutide, and oral semaglutide.
2. Lipolytic and metabolic peptides — compounds proposed to act on adipose tissue or metabolic enzymes to promote fat oxidation without significantly altering appetite. This family includes AOD-9604, HGH Fragment 176-191, 5-Amino-1MQ, and MOTS-c.

The evidence gap between those two families is enormous and worth stating plainly at the top. The incretin drugs have multi-thousand-patient phase 3 trials published in the New England Journal of Medicine and the Lancet. For the lipolytic peptides on this page, the published record is rodent and cell work; a PubMed search returns no peer-reviewed randomized human obesity trial for AOD-9604, HGH Fragment 176-191, 5-Amino-1MQ, or MOTS-c. Anyone quoting a body-fat percentage for those compounds is quoting something other than a published trial.

This hub is the master reference for GLP-1 peptides and peptides for body recomposition. Below you'll find mechanism explanations, the actual trial numbers with their sources, side effect profiles, monitoring frameworks, and links to deep-dive protocols on each compound. If the whole category is new to you, Peptide 101: what are peptides? covers the vocabulary first and the beginner library collects the rest of the start-here reading; everything we publish is indexed in the guide library.

The Families of Fat Loss Peptides

For comprehensive protocols on each, from this hub or from the wider protocol library:

• Semaglutide complete guide
• Tirzepatide protocol
• Retatrutide protocol
• Oral semaglutide protocol
• AOD-9604 protocol
• Fragment 176-191 protocol
• 5-Amino-1MQ protocol
• MOTS-c protocol
• Tesamorelin protocol

How GLP-1s Work (Semaglutide → Retatrutide)

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the gut after eating. Its natural role is to coordinate the post-meal metabolic response. GLP-1 receptor agonists are pharmaceutical analogs that bind the same receptor with a half-life measured in days instead of minutes.

The Three Mechanisms of GLP-1 Action

1. Central appetite suppression — GLP-1 receptors in the hypothalamus reduce hunger signaling. Many patients describe a quieting of "food noise."
2. Delayed gastric emptying — food sits in the stomach longer, which is also the source of the perioperative aspiration concern described below.
3. Glucose-dependent insulin secretion — pancreatic β-cells release insulin in response to elevated glucose, which is why these drugs rarely cause hypoglycemia in people without diabetes.

Why Dual and Triple Agonists Outperform Mono-Agonists

The numbers escalate across the three generations, and each figure below is from the trial named.

• Semaglutide 2.4 mg weekly, STEP 1 — 1,961 adults with obesity and no diabetes, 68 weeks: mean body weight change −14.9% versus −2.4% on placebo; 50.5% of the semaglutide group lost ≥15% of body weight (PMID 33567185).
• Tirzepatide, SURMOUNT-1 — 2,539 adults, 72 weeks: −15.0% on 5 mg, −19.5% on 10 mg, −20.9% on 15 mg, versus −3.1% on placebo. 57% of the 15 mg group lost ≥20% of body weight, versus 3% on placebo (PMID 35658024).
• Retatrutide, phase 2 — 338 adults, 48 weeks: −24.2% on 12 mg versus −2.1% on placebo, with ≥15% weight loss in 83% of the 12 mg group (PMID 37366315). Note what else that trial reported: dose-dependent increases in heart rate that peaked at 24 weeks before declining. Retatrutide is still investigational.

The mechanistic story usually told for this escalation — GLP-1 reduces intake, GIP adds metabolic flexibility, glucagon raises energy expenditure — is a reasonable reading of the pharmacology, but the trials above compared drugs against placebo, not receptors against each other. Treat the receptor-by-receptor attribution as a hypothesis and the weight numbers as the finding.

For the deepest dive, see the Retatrutide protocol guide and the Tirzepatide protocol. For the head-to-head, tirzepatide vs semaglutide puts SURMOUNT-1 and STEP 1 side by side.

How Lipolytic Peptides Work (AOD-9604, Fragment 176-191)

This is the part of the category where the marketing has run furthest ahead of the literature.

What AOD-9604 Actually Is

AOD-9604 is a synthetic analogue of the lipolytic C-terminal domain of human growth hormone. In obese Zucker rats, 500 µg/kg/day orally for 19 days reduced body weight gain by more than half compared with controls (15.8 g versus 35.6 g), increased lipolytic activity in adipose tissue, and — unlike intact hGH — did not impair insulin sensitivity on euglycemic clamp (PMID 11146367). That is a real, useful result. It is also a rat result about slowed weight gain, not a human result about weight loss.

The β3-Adrenergic Story Is Backwards

The standard claim — that AOD-9604 works by stimulating β3-adrenergic receptors on fat cells — is not what the key paper found. In obese mice and β3-adrenergic receptor knockout mice, both hGH and AOD-9604 reduced body weight and fat and raised β3-AR RNA expression; but in the knockout animals, chronic treatment failed to reproduce the weight and lipolysis changes seen in wild-type controls, while acute AOD-9604 still increased energy expenditure and fat oxidation in those same knockouts. The authors' conclusion is explicit: the lipolytic actions of hGH and AOD-9604 "are not mediated directly through the beta(3)-AR," although both compounds increase β3-AR expression, which may contribute to enhanced lipolytic sensitivity (PMID 11713213).

So the honest mechanism statement is: AOD-9604 raises β3-AR expression and increases lipolytic sensitivity in rodents, by a pathway that is not direct β3-AR agonism and is not fully characterized.

What Cannot Be Said About Human Efficacy

The figures that circulate for AOD-9604 in humans — "a 12-week trial showed 2–3% body weight reduction," "phase 2b, 1 mg/day, 2.6%" — do not correspond to any randomized human obesity trial indexed on PubMed. They have been removed from this page. If you have seen them quoted, ask what the citation is; the published human-facing AOD-9604 literature on PubMed consists largely of doping-control detection and metabolism work.

The same applies to HGH Fragment 176-191, for which no human obesity trial could be located, and to the common claim that the fragments deliver GH's fat-burning effect "without elevating IGF-1." That IGF-1 claim is plausible from the rodent data but has not been demonstrated in a published human trial.

Detailed protocols, with their own sourcing:

• AOD-9604 protocol
• HGH Fragment 176-191 protocol
• AOD-9604 + Tesamorelin stack

The Metabolic Enhancers Are Earlier Still

5-Amino-1MQ belongs to a class of small-molecule nicotinamide N-methyltransferase (NNMT) inhibitors. In a study of methylquinolinium-scaffold NNMT inhibitors with primary amine substitutions — the chemical family 5-amino-1MQ sits in — the compounds suppressed lipogenesis in cultured adipocytes, and a potent inhibitor given systemically to diet-induced obese mice significantly reduced body weight and white adipose mass and decreased adipocyte size without reducing food intake (PMID 29155147). Mice, not people.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA that activates AMPK and appears to target skeletal muscle. MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity (PMID 25738459). Again: mice.

See the 5-Amino-1MQ protocol and MOTS-c protocol.

Tesamorelin — The One Approved GH-Axis Fat Compound

Tesamorelin (GHRH 1-44) is FDA-approved for a narrow indication: reduction of excess abdominal fat in people with HIV-associated lipodystrophy. The pivotal data is worth knowing precisely, because it is often paraphrased into something broader.

In a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials (806 antiretroviral-treated patients with excess abdominal fat), daily tesamorelin 2 mg produced a −15.4% treatment effect on visceral adipose tissue by CT at 26 weeks, with no significant change in abdominal subcutaneous adipose tissue, significant reductions in triglycerides, and a mean IGF-1 increase of 108 ng/mL (PMID 20554713).

Three things follow. It is a visceral-fat drug, not a subcutaneous-fat drug. It does raise IGF-1, so it is not an "IGF-1-neutral" option. And the population studied was HIV-associated lipodystrophy, not general obesity — extrapolating to a healthy person seeking recomposition is exactly that, an extrapolation.

Tesamorelin protocol

Comparison: Which Peptide for Which Goal

Different goals point to different tools. This table maps scenarios to approaches; it deliberately omits doses, which belong with a prescriber and in the linked protocol guides.

See the body recomposition protocol for how this is put together in practice.

Realistic Expectations

Trial participants are highly adherent, intensively supported, and enrolled in structured lifestyle interventions. Real-world results are generally lower. The trial figures are the ceiling, not the forecast.

Published Trial Weight Loss

The doses in that table are the doses those trials used, reported as such. They are not a recommendation, and none of these is a drug you should be dosing without a prescriber.

Sources of Individual Variability

• Baseline BMI — a higher starting weight changes both the absolute and percentage arithmetic
• Tolerability of titration — in SURMOUNT-1, adverse events caused discontinuation in 4.3–7.1% of tirzepatide participants versus 2.6% on placebo (PMID 35658024)
• Protein intake and resistance training — the strongest lever you control over body composition rather than scale weight
• Sleep, stress, alcohol — real modifiers, though the size of the effect on GLP-1 response specifically has not been quantified in a trial

Frame expectations around the lower end of the trial figures rather than the headline. In STEP 1, 69.1% of the semaglutide group lost at least 10% of body weight and 50.5% lost at least 15% (PMID 33567185) — so a double-digit result was the common outcome in a trial population, and roughly half did not reach 15%.

Sample Protocols

Every incretin drug on this page is a prescription medication with a labelled titration schedule. Publishing a dosing table on a hub page would be a worse version of the prescribing information, so this section describes structure rather than amounts. Actual dosing belongs with your prescriber, and the compound-specific guides carry the detail with sourcing.

Structure 1 — Incretin-Led Weight Loss

Start low, escalate on the schedule your prescriber sets, and expect gastrointestinal side effects to cluster around dose increases — in SURMOUNT-1 the most common adverse events were gastrointestinal and occurred primarily during dose escalation (PMID 35658024). Hold at the lowest dose that is still producing progress rather than escalating by default. Pair with resistance training and a deliberate protein target from day one, not after you notice muscle loss. Full detail: Tirzepatide protocol, Semaglutide complete guide.

Structure 2 — GH-Axis, Non-Incretin

For someone not ready for an incretin drug, the GH-axis route (sermorelin, tesamorelin) is the one with any controlled human data behind it, and tesamorelin's data is specific to visceral fat in a specific population. Expect modest scale movement. Monitor IGF-1. Full detail: Sermorelin protocol, Tesamorelin protocol, GH peptide stacking guide.

Structure 3 — Body Recomposition

A modest deficit, heavy resistance training, and a high protein intake do most of the work here. The peptide layer is an adjunct to that, not a replacement for it. See the body recomposition protocol.

Side Effects & Safety

Common (Incretin Class)

Gastrointestinal effects dominate and are concentrated during dose escalation. In OASIS 1, gastrointestinal adverse events — mostly mild to moderate — were reported in 80% of participants on oral semaglutide 50 mg versus 46% on placebo (PMID 37385278). In STEP 1, nausea and diarrhea were the most common adverse events, typically transient and mild-to-moderate, and 4.5% of the semaglutide group discontinued for gastrointestinal reasons versus 0.8% on placebo (PMID 33567185).

Also commonly reported: constipation, reflux, fatigue during the steepest part of the deficit, and injection-site irritation.

Gallbladder and Biliary Disease — Quantified

This one has a good meta-analysis behind it. Across 76 randomized trials and 103,371 patients, GLP-1 receptor agonist use was associated with an increased risk of gallbladder or biliary disease (relative risk 1.37, 95% CI 1.23–1.52), driven by cholelithiasis, cholecystitis, and biliary disease. The risk was higher at higher doses and with longer use — and notably higher in the weight-loss trials specifically (RR 2.29, 95% CI 1.64–3.18) than in the diabetes trials (RR 1.27) (PMID 35344001). If you develop right-upper-quadrant pain on one of these drugs, that is a same-day call to your clinician.

Other Serious Considerations

• Acute pancreatitis — listed in the prescribing information for this class; presents as severe abdominal pain radiating to the back and warrants immediate evaluation.
• Medullary thyroid carcinoma — the boxed warning for semaglutide and tirzepatide derives from rodent C-cell tumour findings; the drugs are contraindicated with a personal or family history of MTC or MEN-2. Whether the rodent finding translates to humans has not been established.
• Diabetic retinopathy progression — a labelled concern in some diabetic populations during rapid glucose normalization.
• Hypoglycemia — rare without diabetes; a real risk in combination with insulin or sulfonylureas.
• Mood changes and suicidal ideation — reports have been the subject of regulatory review; a causal relationship has not been established, but it is worth raising with your prescriber if it applies to you.

Muscle Loss Is a Side Effect, Not a Footnote

A 2026 systematic review of body-composition outcomes from randomized trials of liraglutide, semaglutide, tirzepatide, and dulaglutide found that loss of muscle-related indices exceeded prespecified benchmarks in about two thirds of incretin-based interventions — and in nearly half of the non-pharmacologic interventions that produced comparable weight loss (PMID 41996180). Two readings follow: the muscle-loss concern with these drugs is real and measured, and it is substantially a consequence of rapid weight loss in general rather than something unique to the drugs.

Lipolytic Peptide Safety

The "remarkably clean side effect profile" often claimed for AOD-9604 and Fragment 176-191 rests on an absence of human trials, not on a body of safety data. The one relevant published comparison is that AOD-9604 did not impair insulin sensitivity in obese Zucker rats, where intact hGH did (PMID 11146367). That is encouraging and it is not a human safety profile.

Absolute Contraindications for Incretin Drugs

Personal or family history of medullary thyroid carcinoma, MEN-2, prior pancreatitis, pregnancy or planned pregnancy, and severe gastroparesis.

Drug Interactions and Surgery

GLP-1 receptor agonists slow gastric emptying, which changes absorption kinetics for oral medication taken alongside them.

Notable Interactions

• Oral contraceptives — absorption may be affected; ask about backup contraception during initiation and escalation
• Levothyroxine — narrow therapeutic window; recheck TSH after starting
• Warfarin — monitor INR
• Insulin and sulfonylureas — increased hypoglycemia risk; doses usually need reducing
• Narrow-therapeutic-index anticonvulsants — monitor levels
• NSAIDs — additive gastrointestinal burden
• Alcohol — amplified nausea

Surgery: the Evidence Behind the Guidance

The perioperative concern is not theoretical. In a prospective cross-sectional gastric-ultrasound study of 124 patients who had followed standard preprocedural fasting guidelines, increased residual gastric content was present in 56% of once-weekly GLP-1 RA users versus 19% of non-users — an adjusted prevalence ratio of 2.48 (95% CI 1.23–4.97). Critically, there was no association between how long the drug had been held and the prevalence of increased residual gastric content (adjusted OR 0.86, 95% CI 0.65–1.14) (PMID 38446466).

That last finding is why blanket "hold it for a week and you're fine" advice is not well supported by this study. Tell both your prescriber and your anesthesiologist that you are on one of these drugs, well in advance, and let them make the call.

The "Ozempic Face" Problem

Rapid weight loss without adequate protein and resistance training produces predictable cosmetic consequences: facial volume loss and soft-tissue loss elsewhere. The underlying issue is that fat is not the only tissue being lost.

The measured version of this is the body-composition review above: muscle-related losses exceeded prespecified benchmarks in about two thirds of incretin interventions studied, and in nearly half of non-drug interventions producing weight loss (PMID 41996180). Skin and connective tissue also do not retract proportionally, and that part depends on age and rate of loss rather than on anything you inject.

How to Reduce It

1. Prioritise protein — a deliberate daily target, set with a clinician or dietitian against your lean mass, not a number from a hub page.
2. Resistance training several times per week — the only intervention with a direct mechanism for preserving muscle. Cardio alone does not do this.
3. Slow the rate of loss — resist escalating to the maximum tolerated dose by default.
4. Do not stack self-imposed severe restriction on top of maximal drug-induced appetite suppression — the drug creates the deficit; adding a crash diet creates malnutrition.
5. Measure, don't guess — a DXA scan distinguishes fat loss from lean-mass loss in a way the bathroom scale cannot.
6. Discuss GH secretagogues with a clinician if lean-mass loss is documented. Note that this is a reasonable hypothesis rather than a proven strategy: no randomized trial has tested adding a GH secretagogue to an incretin drug for lean-mass preservation. See GH peptide stacking.

What to Do When You Plateau

Plateaus are near-universal on incretin therapy. The playbook below is clinical practice and community experience rather than trial evidence, and is flagged as such.

1. Confirm the plateau is real. A two-to-three-week stall is normal weight variability. Judge after four-plus weeks of consistent measurement.
2. Re-examine adherence. Tracking food or eyeballing it? Alcohol creeping up? Protein dropping because appetite is suppressed?
3. Discuss the next titration step with your prescriber if you are below your maximum tolerated dose. SURMOUNT-1 showed a clear dose-response — −15.0%, −19.5%, −20.9% across 5, 10, and 15 mg (PMID 35658024) — so more drug does generally mean more loss, at the cost of more gastrointestinal effects.
4. Intensify resistance training. More muscle raises resting energy expenditure, and it protects the thing you actually want to keep.
5. Consider a compound switch with your prescriber. This is common practice; there is no head-to-head trial of switching after a plateau to support it as a strategy.

Adding a lipolytic peptide is frequently recommended in community settings for plateaus. Given that no human obesity trial of those compounds could be located, this hub does not recommend it as an evidence-based step.

Maintenance After Stopping

The most important question for anyone starting incretin therapy: what happens when I stop? Two trials answer it directly, and they are often conflated.

The STEP 1 Extension — What Regain Looks Like

In an off-treatment extension of STEP 1, 327 participants were followed for a year after all treatment and lifestyle intervention stopped at week 68. Mean weight loss to week 68 had been 17.3% with semaglutide. By week 120, semaglutide participants had regained 11.6 percentage points of that loss — about two thirds — leaving a net 5.6% below baseline. Cardiometabolic improvements reverted toward baseline for most variables (PMID 35441470).

(Earlier versions of this page attributed the two-thirds regain figure to STEP 4. That was wrong: the regain data is from the STEP 1 extension.)

STEP 4 — What Continuing Looks Like

STEP 4 randomized 803 people who had already titrated to semaglutide 2.4 mg either to continue it or to switch to placebo. Over the next 48 weeks, those who continued lost a further 7.9% of body weight; those switched to placebo gained 6.9% — a 14.8 percentage point difference (PMID 33755728).

What That Implies

Both trials point the same direction, and it is the direction the STEP 1 extension authors state outright: the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain the improvements. Planning for indefinite treatment, at the lowest dose that holds your weight, is the option with data behind it. A gradual taper with aggressive lifestyle consolidation is reasonable to attempt with a clinician; no trial has shown it works at scale. Bridging to a lipolytic peptide during withdrawal is a community practice with no supporting human trial.

Bloodwork & Monitoring

See the broader bloodwork checklist for a full panel.

Baseline Panel

CBC; comprehensive metabolic panel; HbA1c and fasting glucose; fasting insulin and C-peptide; lipase and amylase; TSH, free T3, free T4; lipid panel; hs-CRP; vitamin D, B12, ferritin and iron studies; calcitonin only if there is an MTC or MEN-2 concern.

On Therapy

Repeat the metabolic panel, HbA1c, lipids, lipase, and TSH at a schedule your clinician sets, and check lipase immediately if pancreatitis is suspected. A DXA scan is the single most informative addition here, because it separates fat loss from lean-mass loss — which, given that muscle-related losses exceeded benchmarks in about two thirds of incretin interventions reviewed (PMID 41996180), is the thing most worth knowing. If you are running a GH-axis compound, IGF-1 belongs on every panel: tesamorelin raised mean IGF-1 by 108 ng/mL in its phase 3 pool (PMID 20554713).

What to Watch For

Rising lipase with abdominal pain; new right-upper-quadrant pain (see the gallbladder data above); rapid TSH change if you take thyroid medication; falling B12 with reduced intake; and documented lean-mass loss on DXA, which means the training and protein side needs work rather than the drug side.

Cost, Access, and Regulatory Status

Cost is the largest practical barrier, and the regulatory picture around compounded versions has moved substantially in 2026. Prices for branded products are volatile and are not listed here, because a price table on a hub page goes stale faster than anything else on it — check the manufacturer's current savings programme and your own formulary. What we do publish is the price-per-milligram index, which normalizes list, wholesale and manufacturer self-pay prices to dollars per milligram, dates every figure, and says plainly where no published price exists.

Compounded GLP-1s: the Current Position

• On 2026-04-30 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need; the comment period closed 2026-06-29 (FDA). Both compounds carry their own dated row on the tracker: semaglutide and tirzepatide.
• The litigation went against compounders: the Fifth Circuit decided Outsourcing Facilities Association v. FDA on 2026-08-27 (revised 2026-09-01), affirming, with a companion tirzepatide case the same day (opinion PDF).
• FDA has continued enforcing against telehealth marketing of compounded GLP-1s, beginning with 30 warning letters on 2026-03-03 (FDA).
• On "personalized dosing," FDA reiterated on 2026-04-01 the 2018 "essentially a copy" policy: generally no action against a 503A pharmacy filling four or fewer prescriptions a month where a clinical difference is documented before the prescription is written.

Insurance Gotchas

Most commercial plans cover these drugs for type 2 diabetes far more readily than for weight management alone. BMI thresholds, prior authorization, and step-therapy requirements are close to universal, and some employers carve weight-management coverage out entirely.

Research-Chemical Peptides

AOD-9604, HGH Fragment 176-191, 5-Amino-1MQ, and MOTS-c are sold as research chemicals, not as approved drugs, and pricing varies widely. Verify the certificate of analysis — see the COA reading guide, vendor red flags, and the compounding pharmacy guide, collected in the sourcing library. AOD-9604's own dated FDA row is on the tracker as AOD-9604.

Where Peptide Compounding Stands More Broadly

On 2026-04-15 the FDA announced the removal of 12 peptides from the 503A "Category 2" do-not-compound list, and the agency's bulk-substances page was updated on 2026-04-22 to reflect it. The Pharmacy Compounding Advisory Committee met 2026-07-23 and 24 and recommended six of the seven peptides it considered — including BPC-157, KPV, TB-500, and MOTS-c — while rejecting emideltide. Those recommendations are advisory only; notice-and-comment rulemaking is still required, and none of these substances is on the 503A Bulks List today. Full detail: the current FDA status of every peptide we cover.

Stacking Considerations

Stacking is where this category generates the most confident claims with the least evidence. Each item below is labelled with what supports it.

Incretin + BPC-157 (Gut Protection)

Widely used on the theory that BPC-157 protects the gut lining and eases nausea and reflux during titration. No human trial supports this combination, and BPC-157 itself is not an approved drug. See BPC-157 complete guide.

Incretin + GH Secretagogue (Lean Mass Preservation)

Mechanistically reasonable and increasingly common. No randomized trial has tested it. Given that muscle-related loss is a measured problem with incretin therapy (PMID 41996180), it is a hypothesis worth discussing with a clinician — while remembering that training and protein are the interventions with actual evidence. Framework: GH peptide stacking guide.

Tesamorelin + AOD-9604 (Visceral Plus Subcutaneous)

The rationale is that tesamorelin addresses visceral fat, which it demonstrably does (PMID 20554713), while AOD-9604 addresses subcutaneous fat, which has not been demonstrated in humans. Half of this stack has phase 3 data and half has rodent data. See AOD-9604 + Tesamorelin stack.

The Companions That Are Not Optional

Resistance training, a deliberate protein target, sleep, hydration (these drugs blunt thirst cues as well as hunger cues), and attention to electrolytes during rapid loss. These are the parts of any fat-loss stack with the least controversy and the most leverage.

Frequently Asked Questions: Fat Loss Peptides

What are the best peptides for fat loss? On published evidence, tirzepatide and retatrutide produce the largest weight loss — 20.9% at 72 weeks on the 15 mg arm of SURMOUNT-1 (PMID 35658024) and 24.2% at 48 weeks on the 12 mg arm of the retatrutide phase 2 trial (PMID 37366315) — with semaglutide behind them at 14.9% at 68 weeks in STEP 1 (PMID 33567185). Nothing in the lipolytic or metabolic-enhancer category has a published human obesity trial, so "best" in that group is a marketing claim rather than a finding. See the Tirzepatide protocol and Retatrutide guide.

How much weight can I expect to lose on semaglutide versus tirzepatide? In their pivotal trials, semaglutide 2.4 mg produced a mean 14.9% reduction at 68 weeks (PMID 33567185) and tirzepatide 15 mg produced 20.9% at 72 weeks (PMID 35658024), against placebo arms losing 2.4% and 3.1%. Real-world results are generally lower, because trial participants are more adherent and more supported than most patients. Read the Semaglutide complete guide for full data.

Do peptides like AOD-9604 actually work? Not on any published human evidence. In obese Zucker rats, AOD-9604 more than halved body weight gain over 19 days without impairing insulin sensitivity, and in mice it reduced body weight and fat. No randomized human obesity trial of AOD-9604 appears on PubMed, and the percentage figures quoted for it online do not trace to one. Full mechanism in the AOD-9604 protocol.

Will I regain weight when I stop? Most likely yes. In the STEP 1 off-treatment extension, participants regained 11.6 of the 17.3 percentage points they had lost — about two thirds — within a year of stopping, and most cardiometabolic improvements reverted toward baseline (PMID 35441470). In STEP 4, people switched to placebo gained 6.9% over 48 weeks while those who continued lost a further 7.9% (PMID 33755728). Plan for ongoing treatment or for a very deliberate, supervised transition.

Are oral GLP-1s as effective as injectable? Oral semaglutide at 50 mg daily produced a 15.1% mean weight reduction at 68 weeks in OASIS 1 (PMID 37385278), which is in the same range as the 14.9% seen with injectable semaglutide 2.4 mg weekly in STEP 1 (PMID 33567185). They have not been compared head to head in that population, so "comparable" is an inference across trials rather than a direct finding. The dosing conditions are more demanding — fasted, plain water, and a wait before eating. See the oral semaglutide protocol.

Can I stack GLP-1s with other peptides? People do, most often with BPC-157 for gut symptoms or a GH secretagogue for lean mass. No human trial supports either combination, and both involve compounds that are not approved drugs. Discuss anything you add with the clinician who prescribes your incretin drug, especially anything that adds gastrointestinal burden.

What's the difference between Fragment 176-191 and AOD-9604? Both derive from the lipolytic C-terminal domain of human growth hormone, with AOD-9604 being the analogue developed for stability and the one with the published rodent pharmacology. Neither has a published human obesity trial, so claims that one outperforms the other rest on user report. Compare in the Fragment 176-191 protocol.

Is 5-Amino-1MQ safe for fat loss? It should be treated as experimental. The supporting work is preclinical: NNMT inhibitors of its chemical class suppressed lipogenesis in cultured adipocytes and reduced body weight and white adipose mass in diet-induced obese mice without reducing food intake. There is no human safety or efficacy data. See the 5-Amino-1MQ protocol.

How do I avoid muscle loss while losing fat with peptides? Resistance training and a deliberate protein target are the two interventions with a mechanism and evidence behind them, and slowing the rate of loss helps. This matters more than people assume: a systematic review of randomized trials found muscle-related losses exceeding prespecified benchmarks in about two thirds of incretin-based interventions. Get a DXA scan rather than guessing from the scale.

Do I need to stop my GLP-1 before surgery? Tell your anesthesiologist and your prescriber, and let them decide together. The evidence is more awkward than the usual advice implies: in a gastric-ultrasound study, GLP-1 users had increased residual stomach contents far more often than non-users despite following standard fasting rules, and how long the drug had been held made no measurable difference to that. Standard fasting guidance may simply be inadequate in this group, so this is a conversation to have well before the procedure date.

Featured Protocols on Peptides.NYC

Incretin Receptor Agonists

• Semaglutide: The Complete Protocol Guide
• Tirzepatide (Mounjaro): Dual-Agonist Protocol
• Retatrutide: Triple Agonist Guide
• Oral Semaglutide (Rybelsus): Complete Guide

Lipolytic and Metabolic Peptides

• AOD-9604: The Fat Loss Fragment Protocol
• HGH Fragment 176-191: Targeted Fat Loss
• 5-Amino-1MQ: NNMT Inhibitor Protocol
• MOTS-c Protocol

Stacks, Context, and Regulation

• Body Recomposition Protocol
• AOD-9604 + Tesamorelin Stack
• Tesamorelin: FDA-Approved GH Protocol
• Bloodwork Checklist
• FDA Peptide Status Tracker

Related Hubs

• Muscle & Performance Peptide Hub — preserving and building lean mass
• Hormone Optimization Hub — the endocrine context for GH-axis compounds
• Longevity Peptide Hub — MOTS-c and the metabolic-ageing overlap
• Healing & Recovery Peptide Hub — BPC-157 and the gut-protection claims

Reminder: This hub is educational content only. Peptide therapy for weight loss involves prescription medications, real medical risks, and individual factors that require professional evaluation. Work with a licensed clinician before starting any protocol.

Selected References

Every PMID linked above points to the PubMed record for that paper, so you can check the claim against the abstract yourself.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. PMID 33567185 · doi:10.1056/NEJMoa2032183
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022. PMID 35658024 · doi:10.1056/NEJMoa2206038
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023. PMID 37366315 · doi:10.1056/NEJMoa2301972
4. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. PMID 37385278 · doi:10.1016/S0140-6736(23)01185-6
5. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015. PMID 26132939 · doi:10.1056/NEJMoa1411892
6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. PMID 35441470 · doi:10.1111/dom.14725
7. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PMID 33755728 · doi:10.1001/jama.2021.3224
8. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Internal Medicine. 2022. PMID 35344001 · doi:10.1001/jamainternmed.2022.0338
9. Sen S, Potnuru PP, Hernandez N, et al. Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surgery. 2024. PMID 38446466 · doi:10.1001/jamasurg.2024.0111
10. Batsis JA, Gavras A, Gross DC, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Annals of Internal Medicine. 2026. PMID 41996180 · doi:10.7326/ANNALS-25-00478
11. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism. 2010. PMID 20554713 · doi:10.1210/jc.2010-0490
12. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000. PMID 11146367 · doi:10.1159/000053183
13. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. PMID 11713213 · doi:10.1210/endo.142.12.8522
14. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018. PMID 29155147 · doi:10.1016/j.bcp.2017.11.007
15. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID 25738459 · doi:10.1016/j.cmet.2015.02.009

Regulatory statements on this page are sourced to the FDA, the Fifth Circuit opinion, and contemporaneous trade reporting, linked inline. Inclusion here is not endorsement. Nothing on this page is medical advice.

Source: https://peptides.nyc/learn/goal/fat-loss